[1] WYATT R J,JULIAN B A.IgA nephropathy[J].N Engl J Med,2013,368(25):2402-2414.
[2] ZHANG C,ZENG X,LI Z,et al.Immunoglobulin A nephropathy:current progress and future directions[J].Transl Res,2015,166(2):134-144.
[3] SMITH A C,DE WOLFF J F,MOLYNEUX K,et al.O-glycosylation of serum IgD in IgA nephropathy[J].J Am Soc Nephrol,2006,17(4):1192-1199.
[4] PAWAR R D,PATOLE P S,WÖRNLE M,et al.Microbial nucleic acids pay a Toll in kidney disease[J].Am J Physiol Renal Physiol,2006,291(3):F509-516.
[5] SUZUKI Y,TOMINO Y.The mucosa-bone-marrow axis in IgA nephropathy[J].Contrib Nephrol,2007,157:70-79.
[6] KOYAMA A,SHARMIN S,SAKURAI H,et al.Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy[J].Kidney Int,2004,66(1):121-132.
[7] PAPISTA C,LECHNER S,BEN M S,et al.Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction[J].Kidney Int,2015,88(2):276-285.
[8] BERTHELOT L,PAPISTA C,MACIEL T T,et al.Transglutaminase is essential for IgA nephropathy development acting through IgA receptors[J].J Exp Med,2012,209(4):793-806.
[9] CASTILLO N E,THEETHIRA T G,LEFFLER D A.The present and the future in the diagnosis and management of celiac disease[J].Gastroenterol Rep (Oxf),2015,3(1):3-11.
[10] LUDVIGSSON J F,CARD T R,KAUKINEN K,et al.Screening for celiac disease in the general population and in high-risk groups[J].United European Gastroenterol J,2015,3(2):106-120.
[11] NURMI R,METSO M,PÖRSTI I,et al.Celiac disease or positive tissue transglutaminase antibodies in patients undergoing renal biopsies[J].Dig Liver Dis.2018,50:27-31.
[12] KONING F.Pathophysiology of celiac disease[J].J Pediatr Gastroenterol Nutr.2014;59:S1-4.
[13] TJON J M,VAN BERGEN J,KONING F.Celiac disease:how complicated can it get?[J] Immunogenetics,2010,62(10):641-651.
[14] MOELLER S,CANETTA P A,TAYLOR A K,et al.Lack of serologic evidence to link IgA nephropathy with celiac disease or immune reactivity to gluten[J].PLoS One,2014,9(4):e94677.
[15] MAZMANIAN S K,LIU C H,TZIANABOS A O,et al.An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system[J].Cell,2005,122(1):107-118.
[16] MAZMANIANS K,ROUND J L,KASPER D L.A microbial symbiosis factor prevents intestinal inflammatory disease[J].Nature,2008,453(7195):620-625.
[17] VIEIRA S M,PAGOVICH O E,KRIEGEL M A.Diet,microbiota and autoimmune diseases[J].Lupus,2014,23(6):518-526.
[18] MCCARTHY D D,KUJAWA J,WILSON C,et al.Mice overexpressing BAFF develop a commensal flora-dependent,IgA-associated nephropathy[J].J Clin Invest,2011,121(10):3991-4002.
[19] QIN W,ZHONG X,FAN J M,et al.External suppression causes the low expression of the Cosmc gene in IgA nephropathy[J].Nephrol Dial Transplant,2008,23(5):1608-1614.
[20] YOON H J,SHIN J H,YANG S H,et al.Association of the CD14 gene-159C polymorphism with progression of IgA nephropathy[J].J Med Genet,2003,40(2):104-108.
[21] KIRYLUK K,LI Y,SCOLARI F,et al.Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens[J].Nat Genet,2014,46(11):1187-1196.
[22] KANG W,KUDSK K.Is there evidence that the gut contributes to mucosal immunity in humans?[J].JPEN J Parenter Enteral Nutr,2007,31(3):246-258.
[23] WU M Y,CHEN C S,YIANG G T,et al.The emerging role of pathogenesis of IgA nephropathy[J].J Clin Med,2018,7(8).
[24] HEINRICH P C,BEHRMANN I,HAAN S,et al.Principles of interleukin (IL)-6-type cytokine signalling and its regulation[J].Biochem J,2003,374(Pt 1):1-20.
[25] SCAPINI P,BAZZONI F,CASSATELLA M A.Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils[J].Immunol Lett,2008,116(1):1-6.
[26] WOOF J M,KERR M A.The function of immunoglobulin Ainimmunity[J].J Pathol.2006,208:270-282.
[27] COPPOR,AMOREA,PERUZZIL,et al.Innate immunity and IgA nephropathy[J].J Nephrol 2010,23:626-632.
[28] COPPO R.Pediatric IgA nephropathy:clinical and therapeutic perspectives[J].Semin Nephrol,2008,28(1):18-26.
[29] OORTWIJN B D,RASTALDI M P,ROOS A,et al.Demonstration of secretory IgA in kidneys of patients with IgA nephropathy[J].Nephrol Dial Transplant,2007,22(11):3191-3195.
[30] KOVACS T,KUN L,SCHMELCZER M,et al.Do intestinal hyperpermeability and the related food antigens play a role in the progression of IgA nephropathy?I.Study of intestinal permeability[J].Am J Nephrol,1996,16(6):500-505.
[31] SMITH A C,MOLYNEUX K,FEEHALLY J,et al.O-glycosylation of serum IgA1 antibodies against mucosal and systemic antigens in IgA nephropathy[J].J Am Soc Nephrol,2006,17(12):3520-3528.
[32] SUZUKI H,KIRYLUK K,NOVAK J,et al.The pathophysiology of IgA nephropathy[J].J Am Soc Nephrol.2011,22:1795-1803.
[33] FEDORAK R N,BISTRITZ L.Targeted delivery,safety,and efficacy of oral enteric-coated formulations of budesonide[J].Adv Drug Deliv Rev,2005,57(2):303-316.
[34] SUZUKI H,KIRYLUK K,NOVAK J,et al.The pathophysiology of IgA nephropathy[J].J Am Soc Nephrol 2011,22:1795-1803.
[35] WATTS P,SMITH A.Targit technology:coated starch capsules for site-specific drug delivery into the lower gastrointestinal tract[J].Expert Opin Drug Deliv,2005,2(1):159-167.
[36] MATHIESON,P W.What has the immune system got against the glomerular podocyte?[J].Clin Exp Immunol,2003,134(1):1-5.
[37] SMERUD H K,BARANY P,LINDSTRÖM K,et al.New treatment for IgA nephropathy:enteric budesonide targeted to the ileocecal region ameliorates proteinuria[J].Nephrol Dial Transplant,2011,26(10):3237-3242.
[38] FELLSTRÖM B C,BARRATT J,COOK H,et al.Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN):a double-blind,randomised,placebo-controlled phase 2b trial[J].Lancet,2017,389:2117-2127. |
